

AMENDMENTS TO THE CLAIMS UNDER 37 C.F.R. § 1.121(c)(1)


Please cancel claims 1-14 without prejudice.

Please add new claims 15-22.

A complete version of the entire set of pending claims under 37 C.F.R. § 1.121(c)(3) is as follows:

1-14. (CANCELED)

15. (NEW) A compound having the formula:



wherein R₁, R₂, R₃, and R₆ are each independently selected from the group consisting of hydrogen, CH₂OH, CHO, and CH₂NH₂;


Y is selected from the group consisting of selenium, sulfur, oxygen, and NR, wherein R is hydrogen or C₁-C₇ alkyl;

and when at least one of R₁, R₂, R₃, or R₆ is CH₂NH₂, a pharmaceutically acceptable salt of the compound represented thereby; with the proviso that when R₁ and R₂ are both hydrogen, R₃ and R₆ are not both hydrogen.

16. (NEW) The compound of claim 15, wherein R₃ and R₆ are hydrogen.

17. (NEW) The compound of claim 15, wherein the compound is complexed with a cyclodextrin.

18. (NEW) A compound having the formula:




wherein R₁, R₂, R₃, and R₆ are each independently selected from the group consisting of hydrogen, CHO, CH₂OH, and CH₂NH₂;

Y is selected from the group consisting of selenium, sulfur, oxygen, and NR, wherein R is hydrogen or C₁-C₇ alkyl;

and when at least one of R₁, R₂, R₃, or R₆ is CH₂NH₂, a pharmaceutically acceptable salt of the compound represented thereby; with the proviso that R₁ and R₂ are not both hydrogen.

19. (NEW) The compound of claim 18, wherein the compound is complexed with a cyclodextrin.

20. (NEW) A pharmaceutical composition comprising a compound having the formula:



wherein R₁, R₂, R₃, and R₆ are each independently selected from the group consisting of hydrogen, CH₂OH, CHO, and CH₂NH₂;

Y is selected from the group consisting of selenium, sulfur, oxygen, and NR, wherein R is hydrogen or C₁-C₇ alkyl;

and when at least one of R₁, R₂, R₃, or R₆ is CH₂NH₂, a pharmaceutically acceptable salt of the compound represented thereby; with the proviso that at least one of R₁, R₂, R₃, or R₆ is other than hydrogen;

and a pharmaceutically acceptable carrier.

21. (NEW) The composition of claim 20, wherein R₃ and R₆ in the compound are hydrogen.

22. (NEW) The pharmaceutical composition of claim 20, wherein the compound is complexed with a cyclodextrin.